Welcome to our dedicated page for Zhengye Biotechnology Holding SEC filings (Ticker: ZYBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zhengye Biotechnology Holding Limited (ZYBT) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Zhengye Biotechnology files registration and periodic reports with the U.S. Securities and Exchange Commission in connection with its veterinary vaccine business, which focuses on research, development, manufacturing, and sales of vaccines for livestock and other animals.
Key documents for ZYBT include its registration statement on Form F-1, which supported the company’s initial public offering of ordinary shares, and its annual report on Form 20-F, which contains audited financial statements, risk factors, and detailed information about its veterinary vaccine operations in China and abroad. The company also furnishes Form 6-K reports, such as unaudited interim financial statements and management’s discussion and analysis for periods like the six months ended June 30, 2025.
Through this page, users can review how Zhengye Biotechnology reports revenue from swine, poultry, and other vaccines, as well as disclosures on operating expenses, R&D spending, and balance sheet items. Filings may also describe regulatory developments, including Category I New Veterinary Drug approvals granted by the Ministry of Agriculture and Rural Affairs for jointly developed vaccines, and provide context on the company’s geographic reach across China and exports to Vietnam, Pakistan, and Egypt.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface notable items such as liquidity trends or customer concentration. Users can quickly scan annual Form 20-F reports, interim Form 6-K updates, and offering-related documents without reading every page, while still having direct access to the full text from EDGAR for deeper analysis.
Zhengye Biotechnology Holding Limited reported the results of its Annual General Meeting of Shareholders held on March 24, 2026 in Jilin City, China, with virtual participation also available.
The company had 47,391,376 ordinary shares outstanding as of the February 12, 2026 record date, each carrying one vote. A quorum was achieved, with holders of 43,133,362 ordinary shares represented in person or by proxy.
Shareholders voted on five numbered resolutions, all of which received strong support. For example, Resolution No. 1 received 43,092,532 votes for, 24,730 against, and 16,100 abstentions. The other resolutions (Nos. 2–5) showed similarly high levels of approval, confirming shareholder backing for the company’s proposals.
Zhengye Biotechnology Holding Ltd filed an initial ownership report for Chief Operating Officer Liu Zhongyao. This Form 3 filing identifies Liu as an executive officer of the company but does not show any share purchases, sales, exercises, gifts, or other transactions in the data provided.
Zhengye Biotechnology Holding Ltd director files initial ownership report. Sun Wenhua, a director of Zhengye Biotechnology Holding Ltd, submitted a Form 3, which is an initial statement of beneficial ownership of securities. The filing does not report any purchases, sales, or other transactions in the company’s securities.
Zhengye Biotechnology Holding Ltd officer Lian Wei has filed an initial Form 3 as a reporting person. The filing identifies Lian Wei as Vice General Manager of the company and does not list any share transactions or holdings in either common stock or derivative securities.
Zhengye Biotechnology Holding Ltd filed an initial statement of beneficial ownership on Form 3 for Han Aiden, who serves as Co-Chief Executive Officer. The filing does not list any specific holdings or report any stock transactions, and instead establishes Han Aiden as a reporting insider for future disclosures.
Zhengye Biotechnology Holding Limited is calling a March 24, 2026 annual general meeting where shareholders will vote on major board and capital structure changes. The meeting will be held in Jilin, China, with full virtual participation and voting available through an online webcast platform.
Shareholders are asked to elect two new independent directors and re-elect three current directors, while two incumbents retire. A key proposal reclassifies all ordinary shares into a dual-class structure, with Class A ordinary shares carrying one vote and Class B ordinary shares carrying twenty votes each, including 40,000,000 existing shares held by Securingium Holding Limited designated as Class B.
The company also seeks approval for a 20-for-1 share consolidation to help satisfy Nasdaq Listing Rule 5550(a)(2) on the $1.00 minimum bid price. A new memorandum and articles of association would formally embed the dual-class structure, updated authorised capital of 100,000,000 ordinary shares at US$0.0005 par value, and related governance provisions.
Zhengye Biotechnology Holding Limited reported that independent director Wenbin Wang resigned from the board and from the Audit, Compensation, and Nominating and Corporate Governance Committees, effective February 18, 2026. He also stepped down as chairperson of the Compensation Committee.
The company states that Mr. Wang resigned for personal reasons and that there was no disagreement regarding operations, policies, or practices. He confirms he has received all amounts due and releases the company from any related claims.
The resignation leaves a board vacancy that causes the company to fall out of compliance with Nasdaq Listing Rule 5605(b)(1), which requires a majority of independent directors. Zhengye Biotechnology plans to restore compliance by seeking shareholder approval to appoint a new independent director at its annual general meeting in March 2026.
Zhengye Biotechnology Holding Limited filed a Form 6-K as a foreign private issuer, furnishing unaudited consolidated financial statements and notes for the six months ended June 30, 2025. The exhibits also include unaudited consolidated financial statements and notes for the six months ended June 30, 2025 and 2024, together with management’s discussion and analysis of financial condition and results of operations for the same interim period. Related Inline XBRL instance and taxonomy extension files are provided to present the financial data in structured electronic format.
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) filed its first Form 20-F as a foreign private issuer for the fiscal year ended 31 Dec 2024. The Cayman-incorporated holding company owns Chinese operating subsidiaries engaged in animal-health vaccines and related biological products. At year-end the company had 45,666,376 ordinary shares outstanding and reports under U.S. GAAP; it is classified as a non-accelerated filer and emerging-growth company.
The filing contains extensive disclosures on legal and operational risks of operating almost entirely in mainland China. Key themes include:
- Regulatory filings completed: the company has filed and received CSRC approval (8 Jan 2024) for its overseas listing and believes it is currently below thresholds that would trigger CAC cybersecurity or SAMR anti-monopoly reviews.
- Government oversight risk: PRC authorities may intervene in, or impose new rules on, data security, anti-monopoly, biotechnology or foreign listings, potentially causing material changes in operations or rendering ZYBT shares “worthless.”
- HFCA Act exposure: while auditor WWC, P.C. is PCAOB-inspected, future access disputes could lead to trading prohibitions after two consecutive years of blocked inspection, per the amended HFCA Act.
- Cross-border cash-flow limits: dividend payments from PRC subsidiaries are restricted by SAFE rules, statutory reserve requirements and possible future capital-control tightening; similar uncertainties apply to Hong Kong.
- Structural considerations: investors purchase Cayman equity and have no direct ownership in PRC subsidiaries. The group currently operates without a VIE structure but acknowledges Chinese regulators could still disallow the holding-company arrangement.
- Business-specific risks: heavy reliance on swine-vaccine revenue, limited raw-material suppliers, high customer concentration, product-liability exposure and increasing labor costs in China.
No audited financial statements or performance metrics are included in the excerpt provided, so profitability and liquidity cannot be assessed here. Overall, the 20-F emphasizes compliance progress but highlights pervasive regulatory, geopolitical and operational uncertainties that could materially impact valuation and market access.